Reasons to Choose TaiwanUBI Asia in Partnership with UBI

Chang Yi Wang, PhDFounder, UBI

Chairperson, UBI Asia

Functional

Antigenics

UBI / UBI Asia

Molecular

Design of

Functional

Antigens

Adjuvant &

Formulation

Technologies

UBITh ®

Technology

Synthetic

Peptide

Technologies

Antigenic

Combinatorial

LibraryCyt

oto

xic

T

Lym

ph

ocy

te

Neu

tral

izat

ion

An

tib

od

ies

Vaccines andImmunotherapeutics

Immunodiagnostics TherapeuticMonoclonal Antibodies

AntibodyDeimmunization

Core Technology

Vaccines & ImmunotherapeuticsVaccines & Immunotherapeutics

Animal Health Products Human Health ProductsFunctional Antigenics

Canine AllergyTherapeutic

FMDVVaccine &

Diagnostics

LHRH Vaccinefor Boar Taint Removal &

Growth Promotion

LHRH Vaccine as Pet Contraceptive

LHRH Vaccineas Prostate Cancer

Therapeutic

HIV/AIDSVaccine & Therapeutic

AllergyTherapeutic

Alzheimer Disease Therapeutic

SARS Vaccine& Diagnostics

Product PortfoliosProduct Portfolios

Division of AIDS, NIAID, NIH, USA [HIV Immunotherapeutics]

NIAID, NIH, USA [Allergy Immunotherapeutic] NCI, NIH, USA [Prostate Cancer Immunotherapeutic] Baxter, USA BioMerieux (Lyon, France), formerly Organon Teknik

a of Akzo Nobel (Boxtel, Netherlands) Merial (Lyon, France) (JV of Merck and Aventis, larg

est animal health company in the world) The United Laboratories (Zhuhai, China) China Animal Husbandry Industry Corp. (Beijing, Ch

ina)

Business partners and Product Development Sponsors of UBI

Synergy: Traditional Pharma / Innovative Bio

Peptide Pilot Plant

Protein Drug Pilot Plant

Biologics Manufacture Plant

cGMPRoche

GSK

BioPharmaceuticsFoundation in

Taiwan

Toll Manufacture

Pharmaceutics Foundation in Taiwan

Compliance with FDA

International BioPharmaceutics

Company

Specialty Injectables

rowth

SurvivalcGMP

Pharmaceutical Plants

SynergyPharma / Bio

SynergyUBI / UBI Asia

Business Model

UBI UBI

技術轉移技術轉移

UBI AsiaUBI Asia

技術承接技術承接 & &

產品創新研發產品創新研發

Survival: Conservative Nurtures High Risk

cGMP cGMP ManufactureManufacture

•Acquire Roche & GSK cGMP plants:Acquire Roche & GSK cGMP plants: Chemical drugs, Chemical drugs, BiologicsBiologics

19991999 20022002

InnovativeInnovativeR & DR & D

•Peptide based:Peptide based:Vaccine & diagnosticsVaccine & diagnostics•Protein based:Protein based:Therapeutic monoclonal Therapeutic monoclonal antibodiesantibodies

FMDV Vaccine: Ko-T Con ® 口蹄安FMDV Diagnostics

From Genomics to Products Innovation Through Design

UBI Asia

The Vision:

Complete Replacement of Traditional Vaccineswithin 5 Years !!

UBITh® LHRH ImmunotherapeuticBoar Taint Removal Vaccine: Bota Con ® 寶特康Pet Contraceptive VaccineHuman Prostate Cancer Therapeutic

From Genomics to Products Innovation Through Design

UBI Asia

BotaCon ® 寶特康 :

An Immunotherapeutic to eliminate Boar Taint and promote pig growth and

Cattle

Therapeutic Monoclonal AntibodiesTherapeutic Monoclonal Antibodies

UBI Asia

Monoclonal Antibody Humanization (Murine Ab to Human Ab)

Hybridoma, Cesar Milstein & Georges Kohler

Chimeric mAb, Genentech

Fc

Fv

CDR grafting, PDL

1975 19941986

OKT3, 1986, 55 M USD

RePro, 1994, 447 M USD Rituxan, 1997, 298 M USD

Deimmunization, Biovation

1998

Identification of T cell and B cell

antigenic epitopes in Variable regions

Monoclonal Antibody Engineering

Well-Characterized Monoclonal Antibody (B4) Well-Characterized Monoclonal Antibody (B4) directed against HIV receptor complex for directed against HIV receptor complex for treatment of HARRT resistant AIDS patients treatment of HARRT resistant AIDS patients through entry inhibitionthrough entry inhibition

先導工廠

聯亞研發中心

產程發展 &原料藥生產

UBI Asia R & D

UBI Asia provides services to and collaborates with multiple commercial and research institutes

聯亞生產中心

聯亞 cGMP 廠

西藥 &生技藥品劑型生產

配方研發

臨床試驗產品登記

UBIUBI 國際國際臨床臨床 && 事業事業

中心中心

美國、美洲美國、美洲

台台灣灣

UBI AsiaUBI Asia研發研發 && 生產生產

中心中心

中國大陸中國大陸

歐洲歐洲

東南亞東南亞

日本、韓國日本、韓國

Vision: Designer Immunological Products for the treatment, prevention, and diagnosis of

globally significant diseases

Synergy: UBI Asia / UBI

UBI AsiaUBI AsiaR & D CenterR & D Center

Basic Research

ProcessDevelopment

Field & Field & Clinical Trials Clinical Trials

UBIUBIMOEAMOEA NIHNIH

Reasons to Choose TaiwanUBI Asia in Partnership with UBI

• Taiwan government with policies to promote biotechnology

• Taiwan has diligent, entrepreneurial and well-educated human resources

• Operations can be cost effective when compared with the west

• Easy access to fast breaking first hand business information

• Access to huge China market due to similarity in language and cultural background

• Training and testing ground for worldmarket due to its extensive connections to the western world

Join us, and Welcome to Taiwan!